# Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT）

> **NCT05863273** · — · COMPLETED · sponsor: **First Hospital of China Medical University** · enrollment: 360 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Apremilast

## Key facts

- **NCT ID:** NCT05863273
- **Lead sponsor:** First Hospital of China Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-22
- **Primary completion:** 2025-02-10
- **Final completion:** 2025-03-10
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2025-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05863273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05863273, "Real World Study on the Efficacy and Safety of Apremilast in Chinese Patients With Moderate to Severe Plaque Psoriasis, a Multi Center, Prospective, Observational Trial（REACT）". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05863273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*